68 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter, as incurred, in such proportions that such Underwriter
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
, capital requirements and needs for additional financing;
the clinical nature of our business and our ability to successfully advance our current … and disorders, and the challenges we will face due to the novel nature of such approach;
the success of competing therapies that are or become
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
for additional financing;
the clinical nature of our business and our ability to successfully advance our current and future product candidates through … , and the challenges we will face due to the novel nature of such approach;
the success of competing therapies that are or become available;
the initiation, progress
424B4
CGTX
Cognition Therapeutics Inc
8 Jan 24
Prospectus supplement with pricing info
4:11pm
regarding expenses, future revenue, capital requirements and needs for additional financing;
the clinical nature of our business and our ability … to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;
the success
8-K
EX-99.1
0vu4cs dtsob1nw
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-10.1
d0o55jj2 0m0n8wuvsdf
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
EX-4.4
r7wdmhr
23 Dec 22
Shelf registration
4:16pm
S-3
d1panhul252p5
23 Dec 22
Shelf registration
4:16pm
S-3
EX-1.2
m839kd lc9ekm7gf
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
13cz5gyh jwinn9yjvws
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
8-K
EX-99.2
agim4
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
6yp bdx1ri
14 Nov 22
Prospectus supplement with pricing info
6:02am